Trial Profile
Assessing the efficacy and safety of nasal NeuroEpo management in Patients disease with Parkinson stage II-III - mAkEUP
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 16 Oct 2020
Price :
$35
*
At a glance
- Drugs Recombinant erythropoietin (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms mAkEUP
- 12 Nov 2019 Status changed from not yet recruiting to recruiting.
- 07 Mar 2017 New trial record